Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme
Authors:
Open Access
- 6 December 2011
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 15 (2) , 202-209
Abstract
We previously reported the diagnostic efficacy of the age- and prostate volume-adjusted prostate biopsy method (the adjusted biopsy method). Here, we developed a new nomogram for predicting cancer probability at initial biopsy using the adjusted method. Between 2002 and 2010, 1059 Japanese men with PSA levels between 1.1 and 40 ng ml−1 and biopsied for the first time using the adjusted method at Gunma University Hospital were enrolled. All subjects underwent digital rectal examination (DRE) and transrectal ultrasonography (TRUS). Data from the initial 849 subjects were used for development of the nomogram and those from the final 210 subjects were used for internal validation. External validation was conducted using data from two affiliated hospitals where the same adjusted biopsy method was used. The nomogram was developed through logistic regression analysis, and predictive accuracy and performance characteristics were assessed using the area under the curve (AUC) of the receiver operating characteristics and calibration plots. Furthermore, we compared the predictive accuracy of the newly developed nomogram with the ‘Prostate Risk Indicator’ using the development data set, as well as the two external data sets. The AUC of the logistic regression-based nomogram was significantly higher than those of any single clinical parameter. External validation showed significant correlations with the present model. The AUC-receiver operating characteristic of the ‘Prostate Risk Indicator’ was the second largest following the new nomogram using the development data set and one external data set and almost equal to the new nomogram using the other external data set. Nevertheless the present model does not include somewhat subjective findings on TRUS abnormality, which is necessary for the estimation by ‘Prostate Risk Indicator’, the predictive accuracy of the present simple nomogram could be excellent enough to contribute to accurate shared decision-making between doctors and men who are candidates for the adjusted biopsy scheme.Keywords
This publication has 34 references indexed in Scilit:
- Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: Development of a novel pre-biopsy nomogramInternational Journal of Urology, 2010
- Proprostate-specific antigen: Its usefulness in the era of multiple-core prostate biopsyInternational Journal of Urology, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- History of malignancy is a predictor of prostate cancer detection: Incorporation into a pre‐biopsy nomogramInternational Journal of Urology, 2008
- The diagnostic accuracy of the age‐adjusted and prostate volume‐adjusted biopsy method in males with prostate specific antigen levels of 4.1–10.0 ng/mLCancer, 2002
- OPTIMAL COMBINATIONS OF SYSTEMATIC SEXTANT AND LATERALLY DIRECTED BIOPSIES FOR THE DETECTION OF PROSTATE CANCERJournal of Urology, 2001
- THE OPTIMAL SYSTEMATIC PROSTATE BIOPSY SCHEME SHOULD INCLUDE 8 RATHER THAN 6 BIOPSIES:Journal of Urology, 2000
- Systematic 5 Region Prostate Biopsy is Superior to Sextant Method for Diagnosing Carcinoma of the ProstateJournal of Urology, 1997
- The definition and preoperative prediction of clinically insignificant prostate cancer1996
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993